Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology

27-01-2024 | Cinacalcet | Research Letter

Residual kidney function modifies the effect of cinacalcet on serum phosphorus levels among peritoneal dialysis patients

Authors: Miho Murashima, Naohiko Fujii, Shunsuke Goto, Takeshi Hasegawa, Masanori Abe, Norio Hanafusa, Masafumi Fukagawa, Takayuki Hamano

Published in: Journal of Nephrology

Login to get access

Excerpt

Cinacalcet is an activator of calcium-sensing receptors used for the treatment of secondary hyperparathyroidism among the dialysis population. By suppressing parathyroid hormone (PTH) levels and bone resorption, cinacalcet also lowers serum phosphorus levels among hemodialysis patients [1]. On the other hand, among patients with chronic kidney disease stages 3–4, serum phosphorus levels increase after administration of cinacalcet due to suppression of phosphaturic effects of PTH and fibroblast growth factor (FGF)-23 [2, 3]. We hypothesized that the effect of cinacalcet on phosphorus levels would be dependent on residual kidney function among patients on peritoneal dialysis (PD). …
Appendix
Available only for authorised users
Literature
1.
Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM et al (2006) Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium X phosphate. Clin J Am Soc Nephrol 1:305–312CrossRefPubMed
2.
Chonchol M, Locatelli F, Abbound HE, Charytan C, de Francisco AL, Jolly S et al (2009) A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 53:197–207CrossRefPubMed
3.
Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M (2012) Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 27:784–790CrossRefPubMed
4.
Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T et al (2015) An overview of regular dialysis treatment in Japan (As of 31 December 2013). Ther Apher Dial 19:540–574CrossRefPubMed
5.
Revic D, Matovinovic MS, Rasic S, Kes P, Hamzic-Mehmedbasic A (2015) The effect of preserved residual renal function on left ventricular structure in non-anuric peritoneal dialysis patients. Kidney Blood Press Res 40:500–508CrossRef
6.
Wu M, Wu H, Huang X, Ye H, Huang F, Yu X et al (2019) Associations between serum mineral metabolism parameters and mortality in patients on peritoneal dialysis. Nephrology 24:1148–1156CrossRefPubMed
7.
8.
Lopes MB, Karaboyas A, Zhao J, Johnson DW, Kanjanabuch T, Wilkie M et al (2023) Association of single and serial measures of serum phosphorus with adverse outcomes in patients on peritoneal dialysis: results from the international PDOPPS. Nephrol Dial Transplant 38:193–202CrossRefPubMed
9.
Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K et al (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26:1327–1339CrossRefPubMed
Metadata
Title
Residual kidney function modifies the effect of cinacalcet on serum phosphorus levels among peritoneal dialysis patients
Authors
Miho Murashima
Naohiko Fujii
Shunsuke Goto
Takeshi Hasegawa
Masanori Abe
Norio Hanafusa
Masafumi Fukagawa
Takayuki Hamano
Publication date
27-01-2024
Publisher
Springer International Publishing
Published in
Journal of Nephrology
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-023-01863-x
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits